Swedish drug developer Kancera has exercised an exclusive option to develop a former AstraZeneca drug candidate. The small molecule shares a mechanism of action with a clinical-stage therapeutic antibody from Eisai.
Kancera will shortly start Phase I trials with a small molecule drug candidate that inhibits the Fractalkine receptor CX3CR1. Originally developed for multiple sclerosis, the project was abandoned by AstraZeneca PLC in 2013 when AstraZeneca sold its Södertälje facility in Sweden to Acturum.
Kancera (listed on Nasdaq First North since 2011) entered an option agreement in 2015 with Acturum, and acquired the program...
Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
